Literature DB >> 1437505

Future directions in antimicrobial chemotherapy.

R Janknegt1.   

Abstract

New developments in the treatment of bacterial infections are discussed. The most important developments include oral broad-spectrum cephalosporin derivatives and extended-spectrum injectable cephalosporins with improved activity against Gram-positive bacteria. Meropenem is a new carbapenem agent with markedly improved activity against Gram-negative bacteria. Many fluoroquinolones are in various phases of development. The most interesting new compound is sparfloxacin. Azithromycin is a new macrolide which, because of its very long half-life, attains very high levels in most tissues. Potential uses of the newer agents are discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1437505     DOI: 10.1007/bf01962545

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  102 in total

1.  Pharmacokinetics of cefodizime during continuous ambulatory peritoneal dialysis.

Authors:  P Mendes; N Lameire; B Rosenkranz; V Malerczyk; D Damm
Journal:  J Antimicrob Chemother       Date:  1990-11       Impact factor: 5.790

2.  Pharmacokinetics of cefodizime administered intravenously as a single-dose (1.0 and 2.0 g) to healthy adult volunteers.

Authors:  A Bryskier; T Procyk; D Tremblay; B Lenfant; J B Fourtillan
Journal:  J Antimicrob Chemother       Date:  1990-11       Impact factor: 5.790

3.  In vitro evaluation of GR69153, a novel catechol-substituted cephalosporin.

Authors:  M E Erwin; R N Jones; M S Barrett; B M Briggs; D M Johnson
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

4.  Activity of cefepime, ceftazidime, and ceftizoxime against mutants of Enterobacteriaceae and Pseudomonas aeruginosa derepressed for class I beta-lactamase.

Authors:  C C Knapp; J A Washington
Journal:  J Antimicrob Chemother       Date:  1989-12       Impact factor: 5.790

5.  Safety, tolerance, and pharmacokinetics of cefepime administered intramuscularly to healthy subjects.

Authors:  R H Barbhaiya; C A Knupp; J Tenney; R R Martin; D J Weidler; K A Pittman
Journal:  J Clin Pharmacol       Date:  1990-10       Impact factor: 3.126

6.  The postantibiotic effect of meropenem and imipenem on selected bacteria.

Authors:  H L Nadler; D H Pitkin; W Sheikh
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

7.  In vitro antibacterial activity of DR-3355, the S-(-)-isomer of ofloxacin.

Authors:  T Fujimoto; S Mitsuhashi
Journal:  Chemotherapy       Date:  1990       Impact factor: 2.544

8.  Clinical pharmacokinetics of daptomycin.

Authors:  R D Pryka; R M Novak; D K Wagner; K A Rodvold
Journal:  DICP       Date:  1990-03

9.  The pharmacokinetics of meropenem in volunteers.

Authors:  R P Bax; W Bastain; A Featherstone; D M Wilkinson; M Hutchison; S J Haworth
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

10.  In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.

Authors:  A L Barry; P C Fuchs
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.